Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Scott Koenig
AddedFeb 19, 2024
UpdatedMay 31, 2026
Scott Koenig

Scott Koenig

Board Member, Agtc

CrunchbaseLinkedInThe Org

Scott Koenig's Career

Agtc
Agtc

Alachua, FL, US

Board Member· Board
GlycoMimetics
GlycoMimetics

Rockville, MD, US

Board Member· Board
MacroGenics
MacroGenics

Rockville, MD, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Scott Koenig's Career

Agtc
Agtc
Public$195.1M3501999Alachua, FL, US
Board Member· Board

Leadership at Agtc

Anne VanlentAnne VanlentBoard Member
Nicholas MuzyczkaNicholas MuzyczkaCo-Founder
Terence FlotteTerence FlotteCo-Founder
David FellowsDavid FellowsCEO
R. Jude SamulskiR. Jude SamulskiCo-Founder
Barry ByrneBarry ByrneCo-Founder

Similar to Agtc

American Gene Technologies InternationalAmerican Gene Technologies InternationalRockville, MD, USGene Therapyest. 2008American Gene Technologies InternationalRockville, MD, US · est. 2008

AGT develops innovative gene therapies, aiming to cure severe diseases including HIV and cancer.

Series F · $30.2M52
Apertura Gene TherapyApertura Gene TherapyNew York City, NY, USGene Therapyest. 2021Apertura Gene TherapyNew York City, NY, US · est. 2021

Apertura Gene Therapy: A biotech firm pioneering gene therapy for debilitating diseases.

Series A · $67M29
Jaguar Gene TherapyJaguar Gene TherapyLake Forest, IL, USGene Therapyest. 2019Jaguar Gene TherapyLake Forest, IL, US · est. 2019

Jaguar Gene Therapy: Pioneering breakthroughs in gene therapy for severe genetic diseases.

Late Stage Private · $139M71
AavogenAavogenRockville, MD, USGene Therapeuticsest. 2015AavogenRockville, MD, US · est. 2015

US-based AAVogen, a biotech startup, innovates gene therapeutics for muscle wasting diseases.

Seed · $4.7M5
GlycoMimetics
GlycoMimetics
Public$373.4M392003Rockville, MD, US
Board Member· Board

Leadership at GlycoMimetics

John MagnaniJohn MagnaniBoard Member
Harout SemerjianHarout SemerjianBoard Member
Rachel KingRachel KingCo-Founder
Tim PearsonTim PearsonBoard Member
Pat AndrewsPat AndrewsBoard Member
Daniel M. JuniusDaniel M. JuniusBoard Member
MacroGenics
MacroGenics
Public$165.9M3572000Rockville, MD, US
Board Member· Board

Leadership at MacroGenics

Kenneth GalbraithKenneth GalbraithBoard Member
Bill HeidenBill HeidenBoard Member
Ed HurwitzEd HurwitzBoard Member
Jeff BuchalterJeff BuchalterBoard Member
David StumpDavid StumpBoard Member
Jeffrey V. RavetchJeffrey V. RavetchFounder

Similar to MacroGenics

Kyntra BioKyntra BioSan Francisco, CA, USPharmaceuticalsest. 1993Kyntra BioSan Francisco, CA, US · est. 1993

FibroGen, Inc: A global, research-based pharmaceutical company in San Francisco, innovating treatments for unmet medical needs.

Public · $188M592
IgenicaIgenicaBurlingame, CA, USBiopharmaceuticalsest. 2008IgenicaBurlingame, CA, US · est. 2008

Igenica, Inc.: A biotherapeutics firm creating monoclonal antibodies for cancer treatment in the US.

Pre-Seed · $80.6M11
XencorXencorMonrovia, CA, USAntibody Therapiesest. 1997XencorMonrovia, CA, US · est. 1997

US-based Xencor develops advanced monoclonal antibody therapies for cancer, asthma, and autoimmune disorders.

Public · $133.4M281
SeagenSeagenBothell, WA, USCancer Treatmentsest. 1997SeagenBothell, WA, US · est. 1997

Global biotech innovator developing cancer treatments.

Public · $1.7B3.3k

Scott Koenig's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Scott Koenig

Gab-Seok YangGab-Seok YangBoard Member · MacrogenMeenu ChhabraMeenu ChhabraBoard Member · Fore BiotherapeuticsJeong-sun SeoJeong-sun SeoFounder · Macrogen